Compare Intel Corp (INTC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Sana Biotechnology Inc — how do they compare? Intel Corp trades at $104.7 (market cap $566.04B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Intel Corp is far larger — about 676.5× Sana Biotechnology Inc's market cap, and Intel Corp pays a 2.24% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Sana Biotechnology Inc for 23 Days on average.
| INTC | SANA | |
|---|---|---|
Market Cap | $566.04B | $836.71M |
Volume | 118,475,837 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $140.94 | $5.92 |
52-Week Low | $33.62 | $2.68 |
Typical Hold Time | 116 Days | 23 Days |
Enterprise Value | $586.85B | $749.96M |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $107.08, down 5.34% today, but maintains a bullish technical outlook with strong support at $104. The stock has surged over 220% year-to-date amid AI-driven momentum. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.42 exceeding estimates. However, the company posted a net loss of -$267 million in 2025, reflecting margin pressures. Cash flow improved with $6.46 billion net inflow in 2025, though debt levels remain elevated.
Intel's turnaround story hinges on its foundry expansion and AI chip demand, but high valuation ratios and negative profitability metrics pose risks. Analyst consensus is cautious with a $111.72 price target and 54% hold ratings. Competitive threats from TSMC and AMD require careful monitoring for sustained growth.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
